From this study, we could conclude that SDF-1 dominant model (AG+AA) had a higher risk to develop AML and that CXCR4 expression predicts poor prognosis in AML patients and it could represent a novel target for the effective treatment of AML. The gene discussed is CXCL12; the disease is acute myeloid leukemia.